Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study

被引:11
|
作者
Chen, Zhen-Ping [1 ]
Li, Pei-Jing [1 ]
Li, Gang [1 ]
Tang, Ling [1 ]
Zhen, Ying-Zi [1 ]
Wu, Xin-Yi [1 ]
Cheng, Xiao-Ling [1 ]
Luke, Koon Hung [2 ,3 ,4 ]
Blanchette, Victor S. [5 ]
Poon, Man-Chiu [6 ,7 ,8 ]
Ding, Qiu-Lan [9 ]
Wu, Run-Hui [1 ]
机构
[1] Capital Med Univ, Natl Key Discipline Pediat, Beijing Key Lab Pediat Hematol Oncol, Hematol Oncol Ctr,Beijing Childrens Hosp,Minist E, Beijing 100045, Peoples R China
[2] Childrens Hosp Eastern Ontario, Dept Pediat & Lab Med, Ottawa, ON K1H 8L1, Canada
[3] Childrens Hosp Eastern Ontario, Hemophilia Clin, Ottawa, ON K1H 8L1, Canada
[4] Univ Ottawa, Ottawa, ON K1H 8L1, Canada
[5] Univ Toronto, Res Inst, Hosp Sick Children, Dept Pediat & Child Hlth Evaluat Sci,Div Hematol, Toronto, ON M5G 1X8, Canada
[6] Univ Calgary, Foothills Hosp, Dept Med Pediat & Oncol, Calgary, AB T2N 2T9, Canada
[7] Univ Calgary, Foothills Hosp, Southern Alberta Rare Blood & Bleeding Disorders, Calgary, AB T2N 2T9, Canada
[8] Calgary Hlth Reg, Calgary, AB T2N 2T9, Canada
[9] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Lab Med, Sch Med, Shanghai 200025, Peoples R China
关键词
Boys; Factor VIII; Hemophilia A; Pharmacokinetics; DOSE SECONDARY PROPHYLAXIS; RECOMBINANT FACTOR-VIII; HALF-LIFE; FVIII; CHILDREN; RECOVERY; EFFICACY; PLASMA;
D O I
10.4103/0366-6999.233604
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although much attention has been paid to the pharmacokinetics (PKs) of different factor VIII (FVIII) concentrates in persons with hemophilia A (HA), limited information is available in young boys with severe HA. In this study, we aimed to assess the PK parameters of FVIII products in boys with severe HA in China. Methods: A total of 36 boys (plasma-derived [pd]-FVIII, n = 15; recombinant [r] FVIII, n = 21) were enrolled between January 2015 and May 2016 in Beijing Children's Hospital. PK characteristics of FVIII products were studied according to a reduced 4-sampling time point design (1 h, 9 h, 24 h, and 48 h postinfusion). Results: The mean FVIII half-life (t(1/2)) was 10.99 +/- 3.45 h (range 5.52-20.02 h), the mean in vivo recovery (IVR) was 2.01 +/- 0.42 IU/dl per rU/kg (range 1.24-3.02 IU/l per IU/kg) and mean clearance (CL) of FVIII is 4.34 +/- 1.58 ml'kg(-1) h(-1) (range 2.29-7.90 ml.kg(-1) h(-1)). We also analyzed the influence of several parameters that potentially modulate FVIII PK. The age was closely associated with FVIII half-life (R-2 = 0.32, P < 0.01). The t(1/2) of FVIII increased by 0.59 h per year. Besides age, von Willebrand factor antigen (VWF: Ag) also was associated with FVIII half-life (R-2 = 0.52, P < 0.01). Patients with blood Group O had a shorter FVIII half-life than patients with non-O blood group (9.40 +/- 0.68 h vs. 12.3 +/- 0.79 h, t = 2.70, P = 0.01). The FVIII IR correlated with age (R-2 = 0.21, P < 0.01) and VWF: Ag level (R-2 = 0.28, P < 0.01). CL rates were faster in young patients and in those with low-VWF: Ag levels. CL rates of FVIII are higher in blood Group O versus non-blood Group O persons (5.02 +/- 0.38 vs. 4.00 +/- 0.32 ml.kg(-1) h(-1), t = 2.53, P = 0.02). Conclusions: Chinese boys with severe HA have similar PK values to other ethnic groups and large differences in FVIII PK between individual patients. Age, blood group, and VWF: Ag levels are important determining factors for FVIII CL.
引用
收藏
页码:1781 / U28
页数:6
相关论文
共 50 条
  • [1] Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study
    Chen ZhenPing
    Li PeiJing
    Li Gang
    Tang Ling
    Zhen YingZi
    Wu XinYi
    Cheng XiaoLing
    Hung Luke Koon
    Blanchette Victor S
    Poon ManChiu
    Ding QiuLan
    Wu RunHui
    Hematology Oncology Center Beijing Childrens Hospital Capital Medical University Beijing Key Laboratory of Pediatric Hematology Oncology National Key Discipline of Pediatrics Ministry of Education Beijing China
    Department of Pediatrics and Laboratory Medicine and Hemophilia Clinic Childrens Hospital of Eastern Ontario and University of Ottawa Ottawa Ontario KH L Canada
    Department of Pediatrics and Child Health Evaluative Sciences Division of HematologyOncology Research Institute Hospital for Sick Children University of Toronto Toronto Ontario MG X Canada
    Department of Medicine Pediatrics and Oncology and Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program University of Calgary Foothills Hospital and Calgary Health Region Calgary Alberta TNT Canada
    Department of Laboratory Medicine Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai China
    中华医学杂志英文版, 2018, 131 (15) : 1780 - 1785
  • [2] Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
    Chen, Zhenping
    Huang, Kun
    Li, Gang
    Zhen, Yingzi
    Wu, Xinyi
    Ai, Di
    Liu, Guoqing
    Li, Zekun
    Alfonso, Iorio
    Wu, Runhui
    PEDIATRIC INVESTIGATION, 2021, 5 (01) : 38 - 45
  • [3] An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A
    Liu, Hongzhong
    Wu, Runhui
    Hu, Pei
    Sun, Feifei
    Xu, Lihong
    Liang, Yali
    Nepal, Sunil
    Qu, Peng Roger
    Huard, Francois
    Korth-Bradley, Joan M.
    CLINICAL THERAPEUTICS, 2017, 39 (07) : 1313 - 1319
  • [4] Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
    Chen Zhenping
    Huang Kun
    Li Gang
    Zhen Yingzi
    Wu Xinyi
    Ai Di
    Liu Guoqing
    Li Zekun
    Alfonso Iorio
    Wu Runhui
    儿科学研究(英文), 2021, 05 (01) : 38 - 45
  • [5] Factor VIII/factor IX prophylaxis for severe hemophilia
    Carcao, Manuel
    Srivastava, Alok
    SEMINARS IN HEMATOLOGY, 2016, 53 (01) : 3 - 9
  • [6] Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
    Megias-Vericat, Juan Eduardo
    Bonanad, Santiago
    Haya, Saturnino
    Cid, Ana Rosa
    Marques, Maria Remedios
    Ferrada, Alejandra
    Monte-Boquet, Emilio
    Perez-Alenda, Sofia
    Bosch, Pau
    Querol-Giner, Felipe
    Poveda, Jose Luis
    THROMBOSIS RESEARCH, 2021, 205 : 99 - 105
  • [7] Relationship between mutations in severe hemophilia A and risk of inhibitor development: A large single-center study
    Moghadam, Arash Ahmadfard
    Manafzadeh, Amir Reza
    Nikoonia, Mr
    Moazezi, Seyedeh Somayeh
    Nekoei, Khadijeh Dajliry
    Ramezan, Farahnaz
    Bashash, Davood
    Hamidpour, Mohsen
    Tabibian, Shadi
    TRANSFUSION AND APHERESIS SCIENCE, 2024, 63 (06)
  • [8] Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A
    Zhang, Y.
    Roberts, J.
    Tortorici, M.
    Veldman, A.
    St Ledger, K.
    Feussner, A.
    Sidhu, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (06) : 1106 - 1114
  • [9] Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis
    Chowdary, Pratima
    Fischer, Kathelijn
    Collins, Peter W.
    Cotterill, Amy
    Konkle, Barbara A.
    Blanchette, Victor
    Pipe, Steven W.
    Berntorp, Erik
    Wolfsegger, Martin
    Engl, Werner
    Spotts, Gerald
    THROMBOSIS AND HAEMOSTASIS, 2020, 120 (05) : 728 - 736
  • [10] A 5-Year Single-center Experience on the Use of Emicizumab Prophylaxis in Children With Severe Hemophilia A With and Without Factor VIII Inhibitors
    Hasan, Esraa Mohamed Ahmed
    Motwani, Jayashree
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2025, 47 (02) : e83 - e89